Acquisition Will Accelerate Growth Strategy
YORK, Sept. 9, 2022 /PRNewswire/ -- Dominari
Financial, Inc., the financial services subsidiary of AIkido Pharma
Inc., (NASDAQ: AIKI) has entered into an exclusive agreement for
the acquisition of a broker-dealer firm. This is Dominari's first
acquisition since launching in June. Details of the proposed
purchase can be found in the 8K on
file with the SEC.
Dominari Financial was formed with the intention of acquiring
revenue generating assets in the fintech and financial services
industry. "Our goal has always been to move swiftly to execute a
roll-up strategy of wealth management firms that cater to
ultra-high-net worth investors. This transformative purchase not
only accelerates our timetable, but also gives us the
organizational infrastructure and technology needed to scale
Dominari into a financial services powerhouse," said Carlos
Aldavero, President of Dominari.
Kyle Wool, AIkido board member,
acted as matchmaker on the deal and will continue to advise Mr.
Aldavero on the purchase. "The board fully supports the
diversification strategy of which Dominari Financial is the
centerpiece," added Wool. "Once approved by FINRA, this acquisition
will catapult Dominari forward and lays the groundwork for future
acquisitions. I am looking forward to working closely with Carlos
to continue to identify synergistic companies to bring into the
portfolio," he continued.
Upon approval of the transaction by FINRA, this acquisition will
allow Dominari Financial to provide banking and lending services
through a collaborative agreement with a third-party institution,
delivering the full balance sheet to UHNW investors, corporations,
and institutional clients once the deal officially closes.
Dominari Financial, Inc. Mission
Dominari is a dynamic, forward-thinking financial services
company that creates wealth for all stakeholders by capitalizing on
emerging trends in the financial services sector and identifying
early-stage future opportunities that will generate a high rate of
return for investors.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anticancer and antiviral therapeutics. The Company's platform
consists of patented technology from leading universities and
researchers, and we are currently in the process of developing an
innovative therapeutic drug platform through strong partnerships
with world renowned educational institutions, including
The University of Texas at
Austin and University of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also developing a
broad-spectrum antiviral platform that may potentially inhibit
replication of multiple viruses including Influenza virus, SARS-CoV
(coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
SOURCE Dominari Financial, Inc.